Logo image of BXRX

BAUDAX BIO INC (BXRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BXRX - US07160F4046 - Common Stock

0.1864 USD
+0 (+0.59%)
Last: 11/15/2023, 8:21:44 PM
0.17 USD
-0.02 (-8.8%)
After Hours: 11/15/2023, 8:21:44 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BXRX. BXRX was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of BXRX have multiple concerns. BXRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BXRX had negative earnings in the past year.
In the past year BXRX has reported a negative cash flow from operations.
BXRX had negative earnings in each of the past 5 years.
BXRX had a negative operating cash flow in each of the past 5 years.
BXRX Yearly Net Income VS EBIT VS OCF VS FCFBXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

BXRX has a worse Return On Assets (-161.54%) than 88.35% of its industry peers.
Industry RankSector Rank
ROA -161.54%
ROE N/A
ROIC N/A
ROA(3y)-246.2%
ROA(5y)-201.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BXRX Yearly ROA, ROE, ROICBXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400

1.3 Margins

BXRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BXRX Yearly Profit, Operating, Gross MarginsBXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

BXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BXRX has been increased compared to 1 year ago.
Compared to 1 year ago, BXRX has a worse debt to assets ratio.
BXRX Yearly Shares OutstandingBXRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 500K 1M 1.5M
BXRX Yearly Total Debt VS Total AssetsBXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

BXRX has an Altman-Z score of -17.15. This is a bad value and indicates that BXRX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -17.15, BXRX is not doing good in the industry: 86.41% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.15
ROIC/WACCN/A
WACC6.12%
BXRX Yearly LT Debt VS Equity VS FCFBXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 -20M -40M -60M

2.3 Liquidity

A Current Ratio of 0.09 indicates that BXRX may have some problems paying its short term obligations.
BXRX's Current ratio of 0.09 is on the low side compared to the rest of the industry. BXRX is outperformed by 99.03% of its industry peers.
A Quick Ratio of 0.09 indicates that BXRX may have some problems paying its short term obligations.
BXRX has a Quick ratio of 0.09. This is amonst the worse of the industry: BXRX underperforms 99.03% of its industry peers.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.09
BXRX Yearly Current Assets VS Current LiabilitesBXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.23% over the past year.
BXRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.12%.
EPS 1Y (TTM)7.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.38%
Revenue 1Y (TTM)-19.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BXRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.89% on average per year.
The Revenue is expected to grow by 149.06% on average over the next years. This is a very strong growth
EPS Next Y99.19%
EPS Next 2Y41.36%
EPS Next 3Y25.96%
EPS Next 5Y14.89%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y149.06%

3.3 Evolution

BXRX Yearly Revenue VS EstimatesBXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2026 2027 20M 40M 60M 80M
BXRX Yearly EPS VS EstimatesBXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2K -4K -6K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BXRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BXRX Price Earnings VS Forward Price EarningsBXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BXRX Per share dataBXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

BXRX's earnings are expected to grow with 25.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.36%
EPS Next 3Y25.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BXRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BAUDAX BIO INC

NASDAQ:BXRX (11/15/2023, 8:21:44 PM)

After market: 0.17 -0.02 (-8.8%)

0.1864

+0 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2023-11-14/bmo
Earnings (Next)02-21 2024-02-21/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners8.97%
Ins Owner Change0%
Market Cap1.71M
Revenue(TTM)550.00K
Net Income(TTM)-34.44M
Analysts43.33
Price Target24.48 (13033.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-69.86%
Min EPS beat(2)-166.67%
Max EPS beat(2)26.95%
EPS beat(4)1
Avg EPS beat(4)-46.41%
Min EPS beat(4)-166.67%
Max EPS beat(4)26.95%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.39%
EPS NY rev (1m)0%
EPS NY rev (3m)-71.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-44.16
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.06
BVpS-0.18
TBVpS-1.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -161.54%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-246.2%
ROA(5y)-201.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.09
Altman-Z -17.15
F-Score3
WACC6.12%
ROIC/WACCN/A
Cap/Depr(3y)11%
Cap/Depr(5y)240.77%
Cap/Sales(3y)50.24%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.38%
EPS Next Y99.19%
EPS Next 2Y41.36%
EPS Next 3Y25.96%
EPS Next 5Y14.89%
Revenue 1Y (TTM)-19.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y149.06%
EBIT growth 1Y-1230.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.75%
OCF growth 3YN/A
OCF growth 5YN/A

BAUDAX BIO INC / BXRX FAQ

What is the ChartMill fundamental rating of BAUDAX BIO INC (BXRX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BXRX.


What is the valuation status of BAUDAX BIO INC (BXRX) stock?

ChartMill assigns a valuation rating of 1 / 10 to BAUDAX BIO INC (BXRX). This can be considered as Overvalued.


Can you provide the profitability details for BAUDAX BIO INC?

BAUDAX BIO INC (BXRX) has a profitability rating of 0 / 10.